A phase I, randomized, double-blind, two-way crossover study evaluating the safety, pharmacokinetics and pharmacodynamics of Biosimilar Filgrastim (EP2006) versus Filgrastim in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 03 Apr 2015
At a glance
- Drugs Filgrastim (Primary)
- Indications Cancer
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Sandoz